Company Description
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.
Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Ram Aiyar |
Contact Details
Address: One Kendall Square, Building 600-700 Cambridge, Massachusetts 02139 United States | |
| Phone | 617 468 1999 |
| Website | korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001703647 |
| CUSIP Number | 500946108 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President and Director |
| Jeffrey M. Cerio J.D., Pharm.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Kemi Olugemo M.D. | Chief Medical Officer |
| Andrew Fraley Ph.D. | Co-Founder and Advisor |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder and Advisor |
| Vineet Agarwal M.B.A. | Chief Financial Officer |
| Todd Chappell M.B.A. | Chief Operating Officer |
| Oliver Dolan | Senior Vice President of Finance and Principal Accounting Officer |
| Dr. Loic Vincent Ph.D. | Chief Scientific Officer |
| Stephanie Engels | Senior Vice President and Head of People and Culture |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 18, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |